AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
April 16, 2016- 97-98 percent SVR12 achieved with eight weeks of ABT-493 and ABT-530 in genotypes 1-3 hepatitis C virus patients without cirrhosis in SURVEYOR-1 and 2 studies(1,2)
-
April 15, 2016- VIEKIRAX and EXVIERA achieved 96 percent SVR12 in genotype 1 and 100 percent in genotype 4 chronic hepatitis C virus infected patients in a large ongoing real-world study(1)
-
April 15, 2016- 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with and without RBV in GT1 chronic HCV infected patients without cirrhosis who failed previous therapy with DAAs in a modified intent-to-treat analysis
-
April 14, 2016- 100 percent of genotype 1b patients, who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVR48 in a post-hoc analysis no matter whether baseline NS5A RAVs were present(1)
-
April 11, 2016- Novel BCL-2 inhibitor, approved as a single agent, provided 80 percent overall response rate in Phase 2 clinical study in patients with 17p deletion(1)
-
April 07, 2016
-
April 04, 2016- Pediatric Crohn's disease is a chronic, inflammatory condition of the gastrointestinal tract that can have a substantial physical and psycho-social impact.
-
March 30, 2016- Real-world and Phase 3/3b clinical trial data to be presented on VIEKIRAX® and EXVIERA® in genotype 1 and genotype 4 chronic hepatitis C virus infected patients
-
March 08, 2016
-
March 07, 2016- Anti-IL-23 antibody now in Phase 3 for psoriasis demonstrated greater efficacy over ustekinumab in Phase 2 clinical studies with a potential for quarterly dosing
-
March 04, 2016- Approval based on data from the Phase 3 RESONATE™-2 trial showing an 84% reduction in the risk of progression or death with IMBRUVICA compared to chlorambucil
-
March 02, 2016- New research includes further evaluation of the safety and efficacy of HUMIRA in patients with moderate to severe chronic plaque psoriasis, psoriatic arthritis and moderate to severe hidradenitis suppurativa (HS)
-
February 26, 2016- EU label expansion supported by high cure rates shown in TURQUOISE-III study, a dedicated Phase 3b study of VIEKIRAX + EXVIERA without ribavirin for 12 weeks
-
February 26, 2016- FDA also recently granted venetoclax Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) for the treatment of patients with AML
-
February 18, 2016
-
February 10, 2016- Study meets co-primary efficacy endpoints and full results will be presented at a medical conference in 2016
-
January 29, 2016- Reports Full-Year Adjusted EPS of $4.29, Up 29.2 Percent; GAAP EPS of $3.13
-
January 28, 2016- The Elagolix Phase 3 uterine fibroid clinical development program includes two replicate, pivotal, six-month efficacy and safety studies followed by a six-month safety and efficacy extension study.
-
January 28, 2016- An application is currently under review for single agent venetoclax treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including patients with the 17p deletion genetic mutation
-
January 21, 2016
-
January 20, 2016- Marks the second Breakthrough Therapy Designation for venetoclax
-
January 12, 2016· Priority Review granted by the U.S. Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) in adults who have received at least one prior therapy, including patients with 17p deletion
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
